These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 21585373

  • 1. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C, Cui J, Wang C, Li Y, Zhang L, Xiu X, Li Y, Wei N, Zhang L, Wang P.
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [Abstract] [Full Text] [Related]

  • 2. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C, Wang C, Yang H, Zhao X, Wei N, Cui J.
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [Abstract] [Full Text] [Related]

  • 3. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
    Cui J, Li C, Wang C, Li Y, Zhang L, Zhang L, Xiu X, Li Y, Wei N.
    J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
    [Abstract] [Full Text] [Related]

  • 4. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
    Yang W, Yang Z, Fu J, Guo M, Sun B, Wei W, Liu D, Liu H.
    Biomater Sci; 2018 Dec 18; 7(1):419-428. PubMed ID: 30500018
    [Abstract] [Full Text] [Related]

  • 5. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
    Li C, Cui J, Li Y, Wang C, Li Y, Zhang L, Zhang L, Guo W, Wang J, Zhang H, Hao Y, Wang Y.
    Eur J Pharm Sci; 2008 Aug 07; 34(4-5):333-44. PubMed ID: 18573336
    [Abstract] [Full Text] [Related]

  • 6. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
    Li C, Cui J, Wang C, Zhang L, Xiu X, Li Y, Wei N, Li Y, Zhang L.
    J Pharm Pharmacol; 2011 Mar 07; 63(3):376-84. PubMed ID: 21749385
    [Abstract] [Full Text] [Related]

  • 7. Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.
    Zhang W, Wang G, Falconer JR, Baguley BC, Shaw JP, Liu J, Xu H, See E, Sun J, Aa J, Wu Z.
    Pharm Res; 2015 Apr 07; 32(4):1451-61. PubMed ID: 25355460
    [Abstract] [Full Text] [Related]

  • 8. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
    Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD.
    Biochim Biophys Acta; 2007 Mar 07; 1768(3):678-87. PubMed ID: 17208196
    [Abstract] [Full Text] [Related]

  • 9. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
    Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, Bally M.
    Eur J Pharm Biopharm; 2008 Mar 07; 68(3):607-17. PubMed ID: 17904831
    [Abstract] [Full Text] [Related]

  • 10. Novel liposomal gefitinib (L-GEF) formulations.
    Zhou X, Yung B, Huang Y, Li H, Hu X, Xiang G, Lee RJ.
    Anticancer Res; 2012 Jul 07; 32(7):2919-23. PubMed ID: 22753756
    [Abstract] [Full Text] [Related]

  • 11. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
    Li C, Cui J, Wang C, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y.
    Int J Pharm; 2008 Oct 01; 362(1-2):60-6. PubMed ID: 18598745
    [Abstract] [Full Text] [Related]

  • 12. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
    Johnston MJ, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, Leng EC, Karlsson G, Yanko D, Cullis PR.
    Biochim Biophys Acta; 2006 Jan 01; 1758(1):55-64. PubMed ID: 16487476
    [Abstract] [Full Text] [Related]

  • 13. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB.
    Clin Cancer Res; 2004 Oct 01; 10(19):6638-49. PubMed ID: 15475454
    [Abstract] [Full Text] [Related]

  • 14. Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation.
    Zhang W, Wang G, See E, Shaw JP, Baguley BC, Liu J, Amirapu S, Wu Z.
    J Control Release; 2015 Apr 10; 203():161-9. PubMed ID: 25701612
    [Abstract] [Full Text] [Related]

  • 15. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y.
    J Control Release; 2007 Apr 02; 118(2):204-15. PubMed ID: 17239468
    [Abstract] [Full Text] [Related]

  • 16. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
    Li CL, Cui JX, Wang CX, Zhang L, Li YH, Zhang L, Xiu X, Li YF, Wei N.
    Int J Pharm; 2010 May 31; 391(1-2):230-6. PubMed ID: 20214962
    [Abstract] [Full Text] [Related]

  • 17. Sulfosalicylate mediates improved vinorelbine loading into LUVs and antineoplastic effects.
    Li C, Cui J, Wang C, Cao J, Zhang L, Li Y, Liang M, Xiu X, Li Y, Wei N, Deng C.
    J Liposome Res; 2012 Mar 31; 22(1):42-54. PubMed ID: 21696260
    [Abstract] [Full Text] [Related]

  • 18. Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods.
    Yoshino K, Nakamura K, Terajima Y, Kurita A, Matsuzaki T, Yamashita K, Isozaki M, Kasukawa H.
    Biochim Biophys Acta; 2012 Nov 31; 1818(11):2901-7. PubMed ID: 22828450
    [Abstract] [Full Text] [Related]

  • 19. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
    Wehbe M, Malhotra A, Anantha M, Roosendaal J, Leung AWY, Plackett D, Edwards K, Gilabert-Oriol R, Bally MB.
    J Control Release; 2017 Apr 28; 252():50-61. PubMed ID: 28286316
    [Abstract] [Full Text] [Related]

  • 20. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
    Maitani Y, Saito H, Seishi Y, Iwase Y, Yamauchi T, Higashiyama K, Sugino T.
    J Drug Target; 2012 Dec 28; 20(10):873-82. PubMed ID: 23050928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.